Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.
Martina Porter, MD
Advertisement
Martina Porter, MD, vice chair of research, Beth Israel Deaconess Medical Center, Harvard Medical School.
Articles by Martina Porter, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
House Panel Advances Bills to Expand Veterans’ Health Care Access
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
The Oncology Care Model: A Decade of Transformation
5